Decera Clinical Education Oncology Podcast

In this episode, Charles J. Ryan, MD, and Neal D. Shore, MD, FACS, answer questions from a healthcare professional audience on topics related to prostate cancer and PARP inhibition including:Germline and somatic mutation testingManaging adverse events with PARP inhibitorsResistance to PARP inhibitorsImplications of monoallelic vs biallelic BRCA mutationsATM mutations and PARP inhibitor sensitivityPresenters:Charles J. Ryan, MDProfessor of MedicineB.J. Kennedy Chair in Clinical Medical OncologyDirector, Division of Hematology, Oncology and TransplantationDepartment of MedicineUniversity of MinnesotaOncologistDivision of Hematology, Oncology and TransplantationUniversity of Minnesota Health Clinics and Surgery CenterMinneapolis, MinnesotaNeal D. Shore, MD, FACSDirectorCarolina Urologic Research CenterAtlantic Urology ClinicsMyrtle Beach, South CarolinaLink to full program, including downloadable slidesets, expert commentaries, and on-demand webcast:https://bit.ly/2P31ZqF Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Jeremy S. Abramson, MD, MMSc, discusses highlights of the key data from ASH 2020 on the treatment of patients with lymphomas/CLL, with topics including:Approved and Investigational Targeted Therapeutics for CLL  Investigational CAR T-Cell Therapy for Indolent Lymphomas, CLL, and Mantle Cell LymphomaBispecific Antibodies and Other Investigational Targeted Agents for LymphomasTreatment for Older Patients With Hodgkin LymphomaPresenters:Jeremy S. Abramson, MD, MMScAssociate Professor  Department of Medicine  Harvard Medical School  Director, Center for Lymphoma  Massachusetts General Hospital  Boston, MassachusettsContent based on an online CME program supported by educational grants from Amgen; AstraZeneca; Bristol-Myers Squibb; Epizyme, Inc.; GlaxoSmithKline; Incyte Corporation; Janssen Biotech; Karyopharm Therapeutics Inc.; Novartis; PharmaEssentia Corp.; Seattle Genetics; and Takeda Oncology.Link to full program:https://bit.ly/3tyQ9nG    Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Enriqueta Felip, MD, PhD, and Matthew Gubens, MD, MS, discuss evolving practice standards for EGFR-mutated non-small-cell lung cancer with topics including:Biomarker testing and strategiesOptimal first-line therapy in patients with NSCLCManagement of patients with CNS diseaseSelecting therapy for patients with noncanonical mutationsManagement strategies after progression on first-line EGFR TKI therapySelecting therapy for patients with early stage diseasePresenters: Enriqueta Felip, MD, PhDHead, Thoracic Oncology UnitOncology ServiceVall d'Hebron University HospitalBarcelona, SpainMatthew Gubens, MD, MSAssociate ProfessorThoracic OncologyUniversity of California, San FranciscoSan Francisco, CaliforniaContent based on an online CME program supported by an educational grant from AstraZeneca.Link to full program, including associated downloadable slidesets:https://bit.ly/2PpFFHM Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Ignacio Durán, MD, PhD, and Alison Birtle, MD, FRCP, FRCR, interpret the latest clinical data on targeting FGFR in urothelial cancer    Presenters:Ignacio Durán, MD, PhDAssociate ProfessorGU Oncology Program LeaderDepartment of Medical OncologyHospital Universitario Marques de Valdecilla-IdivalSantander, SpainAlison Birtle, MD, FRCP, FRCRHonorary Senior LecturerFaculty of Health and MedicineUniversity of ManchesterManchester, United KingdomConsultant OncologistRosemere Cancer CentreLancashire Teaching HospitalsPreston, Lancashire, United KingdomContent based on an online IME program supported by educational grants from Janssen Pharmaceutica NV.Link to full program:http://bit.ly/3cf28jH  Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Michael J. Pishvaian, MD, PhD, and Rachna Shroff, MD, answer audience questions from a live CCO webinar focused on current best practices and emerging strategies in pancreatic cancer treatment, with questions including:What is your preferred regimen for neoadjuvant therapy in patients with resectable disease?How do you sequence therapy for patients with metastatic pancreatic cancer?How can you manage a patient who develops significant diarrhea with FOLFIRINOX?Are cisplatin and oxaliplatin equally efficacious for patients with BRCA-mutant disease?How should maintenance olaparib be used?Presenters:Michael J. Pishvaian, MD, PhD  Associate Professor of OncologyDirector, Gastrointestinal, Developmental Therapeutics, and Clinical Research ProgramsNCR Kimmel Cancer Center at Sibley Memorial HospitalJohn Hopkins University School of MedicineWashington, DCRachna Shroff, MDAssociate Professor of MedicineChief, Section of GI Medical OncologyDirector, UACC Clinical Trials OfficeThe University of Arizona Cancer CenterTucson, Arizona Content based on an online CME program supported by educational grants from Bristol-Myers Squibb and Ipsen Group.Link to full program:http://bit.ly/314BALT Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Frederick L. Locke, MD, answers audience questions from a live CCO Webinar focused on emerging strategies in the use of CAR T-cell therapy for patients with lymphomas, with questions including:How does the recent approval of lisocabtagene maraleucel and the expanded indication for axicabtagene ciloleucel add to the treatment landscape for DLBCL? Do you see CAR T-cell therapy ever being used in the first-line setting for DLBCL?How should physicians select patients for CAR T-cell therapy vs ASCT in DLBCL?How should physicians sequence CAR T-cell therapy vs BTK inhibitors in MCL?Presenter:Frederick L. Locke, MDCo-LeaderMoffitt Immuno-Oncology ProgramVice Chair and Associate Member Department of Blood and Marrow Transplant and Cellular ImmunotherapyResearch Director and Medical DirectorImmune Cell Therapy ProgramMoffitt Cancer CenterTampa, FloridaContent based on an online CME program supported by educational grants from Bristol-Myers Squibb and Kite Pharma.Link to full program: https://bit.ly/3rDeFCV Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, D. Ross Camidge, MD, PhD, and Joel W. Neal, MD, PhD, answer questions on investigational antibody-drug conjugates for advanced NSCLC  Presenters:Ross Camidge, MD, PhD  Professor of Medicine/Oncology  University of Colorado Cancer CenterAurora, ColoradoJoel W. Neal, MD, PhD  Associate Professor of MedicineDivision of OncologyDepartment of MedicineStanford UniversityAttending PhysicianStanford Cancer InstitutePalo Alto, CaliforniaContent based on an online IME program supported by educational grants from Daiichi Sankyo, Inc .Link to full program:http://bit.ly/3twpIyl  Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Noopur Raje, MD, answers audience questions from a live CCO Webinar focused on emerging strategies in the use of CAR T-cell therapy for patients with multiple myeloma and key toxicities associated with CAR T-cell therapy, with questions including:Now that belantamab mafodotin is approved for relapsed/refractory multiple myeloma, what are your thoughts on how BCMA-directed CAR T-cell therapy might be sequenced? Is there reason to think CAR T-cell therapy would still be efficacious following belantamab mafodotin?Could BCMA-directed CAR T-cell therapy replace transplant in the first-line setting for multiple myeloma?What are key considerations surrounding the use of tocilizumab for managing cytokine-release syndrome?What are some of the longer-term toxicities associated with CAR T-cell therapy? When do they emerge and how long do they typically last?Presenter:Noopur Raje, MDProfessor of MedicineHarvard Medical SchoolDirectorCenter for Multiple MyelomaMassachusetts General Hospital Cancer CenterBoston, MassachusettsContent based on an online CME program supported by educational grants from Bristol-Myers Squibb and Kite Pharma.Link to full program:http://bit.ly/3rDeFCV  Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Dr. Shaji Kumar from the Mayo Clinic and Dr. Sagar Lonial from Emory University discuss highlights of the key data from ASH 2020 on the treatment of patients with multiple myeloma. Topics include:Newly diagnosed multiple myelomaRelapsed/refractory multiple myelomaAnti-BCMA therapy: CAR T-cellsAnti-BCMA therapy: bispecific antibodiesAnti-BCMA therapy: antibody–drug conjugatesNovel targeted agents for relapsed/refractory multiple myelomaPresenters:Shaji K. Kumar, MDMark and Judy Mullins Professor of Hematological MalignanciesChair, Myeloma Amyloidosis Dysproteinemia GroupConsultant, Division of HematologyMayo ClinicRochester, MinnesotaSagar Lonial, MDProfessor and ChairDepartment of Hematology and Medical OncologyChief Medical OfficerWinship Cancer Institute of Emory UniversityAtlanta, GeorgiaLink to the CCO website: http://bit.ly/30EqUn0 Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Jorge Cortes, MD, and Eunice S. Wang, MD, discuss the clinical implications of 3 key studies in acute myeloid leukemia (AML) and chronic myeloid leukemia (CML) presented at the virtual ASH 2020 annual conference. Topics include:  The macrophage immune checkpoint inhibitor magrolimab in AMLThe STAMP inhibitor asciminib in CML (the ASCEMBL trial)Optimal dosing for the TKI ponatinib in CMLPresenters:Jorge Cortes, MDDirector, Georgia Cancer CenterEminent Scholar, Georgia Research AcademyAugusta, GeorgiaEunice S. Wang, MDProfessor, OncologyChief, Leukemia ServiceDepartment of MedicineRoswell Park Comprehensive Cancer CenterBuffalo, New YorkContent supported by educational grants from Amgen; AstraZeneca; Bristol-Myers Squibb; Epizyme, Inc; GlaxoSmithKline; Incyte Corporation; Janssen Biotech; Karyopharm Therapeutics Inc; Novartis; PharmaEssentia Corp; Seattle Genetics; and Takeda Oncology.Link to full program and Capsule Summary downloadable slidesets:https://bit.ly/3tyQ9nG  Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.